New App Note: Afucosylated mAb expression and antibody efficacy


Currently, at least 35 glycoengineered antibodies, with their Fc fucose partially or entirely removed, have been investigated in animal models or clinical trials.

The absence of fucose on the Fc N-glycan increases IgG1 Fc binding affinity to the FcγRIIIa on immune effector cells like natural killer cells. It results in increased antibody-dependent cellular cytotoxicity (ADCC).

Sino Biological’s “FucoFree” eukaryotic expression system provides high-yield and high-throughput afucosylated monoclonal antibody (mAb) production.

Download the new App Note to learn more about:

  • How antibodies work to eliminate the antigens
  • How to lower the fucosylation on Fc
  • “FucoFree” system for high-yield and high-throughput afucosylated mAb expression

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free